CML HealthCare Inc.'s Subsidiary, Hemostasis Reference Laboratory Awarded Contract Extension with Isis Pharmaceuticals MISSISSAUGA, ONTARIO -- (Marketwired) -- 04/19/13 -- CML HealthCare Inc. (TSX:CLC) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, today announced that its subsidiary, Hemostasis Reference Laboratory Inc. ("HRL") has been awarded a contract extension to work with Isis Pharmaceuticals ("Isis") on their Factor XI ("ISIS-FXIRX") Phase II clinical trial. ISIS-FXIRX is an antisense drug designed to treat clotting disorders. HRL is currently the coagulation testing laboratory of choice for ISIS-FXIRX Phase I clinical trial. Under the new contract, HRL will be the specialty coagulation laboratory testing all ISIS-FXIRX Phase II clinical trial samples. HRL has worked closely with Isis in the past to develop specific testing panels that would best suit their needs, including reagent sensitivities for FXI, as well as numerous Thrombin Generation assays. "We are excited to continue strengthening our partnership with ISIS, a leading antisense drug discovery and development company. HRL's technical proficiencies in developing customized testing panels will provide ISIS with the ideal platform to further their clinical trials," said Thomas Wellner, President and Chief Executive Officer of CML. "We look forward to continuing to service contract research organizations, pharmaceutical and biotechnology companies with our in-depth capabilities and unique service offerings." About CML HealthCare Inc. Based in Mississauga, Ontario, CML HealthCare Inc. a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and its subsidiary, Hemostasis Reference Laboratory, a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare. About ISIS-FXIRx ISIS-FXIRx is an antis ense drug discovered and being developed by Isis Pharmaceuticals. ISIS-FXIRx is designed to treat clotting disorders by inhibiting the production of Factor XI, a clotting factor produced in the liver that is an important component of the coagulation pathway. High levels of Factor XI increase the risk of thrombosis, a process involving aberrant blood clot formation responsible for most heart attacks and strokes. Elevated levels of Factor XI also increase the risk of venous thrombosis, a common problem after surgery, particularly major orthopedic procedures, such as knee or hip replacement. People who are deficient in Factor XI have a lower incidence of thromboembolic events with minimal increase in bleeding risk. Contacts: CML HealthCare Inc. Alice Dunning, MBA, CFA Director, Corporate Communications DunningA@cml.ca www.cmlhealthcare.com
CML HealthCare Inc.'s Subsidiary, Hemostasis Reference Laboratory Awarded Contract Extension with Isis Pharmaceuticals
Press spacebar to pause and continue. Press esc to stop.